- Home
- STEC vs DARE Comparison
STEC vs DARE Comparison
Compare STEC & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- DARE
- Stock Information
- Founded
- STEC 2006
- DARE 2015
- Country
- STEC Hong Kong
- DARE United States
- Employees
- STEC N/A
- DARE N/A
- Industry
- STEC
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- DARE Health Care
- Exchange
- STEC NYSE
- DARE Nasdaq
- Market Cap
- STEC 63.8M
- DARE 26.3M
- IPO Year
- STEC 2021
- DARE N/A
- Fundamental
- Price
- STEC $0.74
- DARE $2.39
- Analyst Decision
- STEC
- DARE Strong Buy
- Analyst Count
- STEC 0
- DARE 3
- Target Price
- STEC N/A
- DARE $12.50
- AVG Volume (30 Days)
- STEC 10.9K
- DARE 4.6M
- Earning Date
- STEC 08-05-2025
- DARE 08-11-2025
- Dividend Yield
- STEC N/A
- DARE N/A
- EPS Growth
- STEC N/A
- DARE N/A
- EPS
- STEC N/A
- DARE N/A
- Revenue
- STEC $10,672,000.00
- DARE $25,909.00
- Revenue This Year
- STEC $9,392.20
- DARE $74,787.57
- Revenue Next Year
- STEC N/A
- DARE $141.76
- P/E Ratio
- STEC N/A
- DARE N/A
- Revenue Growth
- STEC N/A
- DARE N/A
- 52 Week Low
- STEC $0.20
- DARE $2.11
- 52 Week High
- STEC $3.25
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- STEC 40.44
- DARE 40.33
- Support Level
- STEC $0.70
- DARE $2.44
- Resistance Level
- STEC $0.80
- DARE $2.80
- Average True Range (ATR)
- STEC 0.08
- DARE 0.66
- MACD
- STEC 0.00
- DARE -0.01
- Stochastic Oscillator
- STEC 38.55
- DARE 3.88
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.